Back to Authors

Gopalakrishnan, Naveen

Mayo Clinic

Division of Gastroenterology and Hepatology

Citations 1

Development and Pilot Testing of Decision Aid for Shared Decision Making in Barrett’s Esophagus With Low-Grade Dysplasia
Krishnamoorthi, Rajesh , Hargraves, Ian , Gopalakrishnan, Naveen, Blevins, Christopher H. , Priyan, Harshith, Johnson, Michele L., Maixner, Kristyn, Wang, Kenneth K, Katzka, David A. , Talwalkar, Jayant A., Iyer, Prasad G. , LeBlanc, Annie

Journal of Clinical Gastroenterology | February 10, 2020 | Volume: 55 | Issue: 1 | Pages: 36-42

10.1097/mcg.0000000000001319 Get It

Goals: To develop an encounter decision aid [Barrett’s esophagus Choice (BE-Choice)] for patients and clinicians to engage in shared decision making (SDM) for management of BE with low-grade dysplasia (BE-LGD) and assess its impact on patient-important outcomes. Background: Currently, there are 2 strategies for management of BE-LGD—endoscopic surveillance and ablation. SDM can help patients decide on their preferred management option. Study: Phase-I: Patients and clinicians were engaged in a user-centered design approach to develop BE-Choice. Phase-I included review of evidence on BE-LGD management, observation of usual care (UC), creation, field-testing, and iterative development of BE-Choice in clinical settings. Phase-II: Impact of BE-Choice on patient-important outcomes (patient knowledge, decisional conflict, and patient involvement in decision making) was assessed using a controlled before-after study design (UC vs. BE-Choice). Results: Phase-I: Initial prototype was designed with observation of 8 clinical encounters. With field-testing, 3 successive iterations were made before finalizing BE-Choice. BE-Choice was paper based and fulfilled the qualifying criteria of International patient decision aid standards. Phase II: 29 patients were enrolled, 8 to UC and 21 to BE-Choice. Compared with UC, use of BE-Choice improved patient knowledge (90.4% vs. 70.5%; P =0.03), decisional comfort (89.6 vs. 71.9; P =0.01), and patient involvement (OPTION score: 27.1 vs. 19.2; P =0.01). Conclusions: BE-Choice is a feasible and effective decision aid to promote SDM in the management of BE-LGD. On pilot testing, BE-Choice had promising impact on patient-important outcomes. A larger multicenter trial is needed to confirm our results and promote widespread use of BE-Choice.